Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
WC10
- Development stage
- Preclinical
- Modality
- Small Molecules
01
Overview
WC10 is a research compound characterized as a functional antagonist of dopamine D3 receptors and dopamine D1/D2 receptors. It was investigated in a prepulse inhibition (PPI) assay in rats to identify D3-mediated antipsychotic properties in vivo. The compound demonstrated the ability to prevent PPI deficits induced by both the mixed D1/D2-like agonist apomorphine and the preferential D3 agonist pramipexole, suggesting its dual D3 and D1/D2 antagonist profile. This assay aims to detect D3 vs. D2 receptor-linked mechanisms of action, potentially offering a more favorable therapeutic profile for conditions like schizophrenia compared to existing antipsychotics.
02
Targets
DRD2 (Dopamine D2 Receptor)DRD3 (Dopamine receptor D3)DRD4 (Dopamine D4 Receptor)
Beyond the preview
Go deeper on WC10.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on WC10.